idebenone has been researched along with Hereditary Optic Neuroretinopathy in 46 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Idebenone was well tolerated, with most adverse events classified as minor." | 2.94 | Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy. ( Acaroglu, G; Banik, R; Black, GCM; Castillo, L; Catarino, CB; Doncel, C; Fraser, CL; Friedburg, C; Halfpenny, CA; Jakubaszko, J; Klopstock, T; Landau, K; Langenegger, SJ; Lincoln, JA; Llòria, X; Lob, F; Matloob, S; Metz, G; Mikazans, O; Muñoz-Negrete, FJ; Newman, NJ; Poulton, J; Priglinger, C; Rudolph, G; Scoppettuolo, E; Silva, M; Subramanian, P; Tamhankar, MA; Toosy, AT; Traber, GL; Vidal, M; Vincent, AL; von Livonius, B; Votruba, M; Zarowski, M; Zermansky, A, 2020) |
| "Treatment with idebenone improved tritan color vision compared with placebo (P = 0." | 2.78 | Effects of idebenone on color vision in patients with leber hereditary optic neuropathy. ( Al-Tamami, J; Büchner, B; Dimitriadis, K; Heck, S; Klopstock, T; Leinonen, M; Meier, T; Rudolph, G; Rummey, C; Seidensticker, F, 2013) |
| "Idebenone was safe and well tolerated." | 2.76 | A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. ( Atawan, A; Bailie, M; Chattopadhyay, S; Chinnery, PF; Dimitriadis, K; Garip, A; Griffiths, PG; Heck, S; Kernt, M; Klopstock, T; Leinonen, M; Meier, T; Metz, G; Petraki, D; Rouleau, J; Rummey, C; Schubert, M; Yu-Wai-Man, P, 2011) |
| "Idebenone is a rapidly absorbed, safe and well-tolerated drug and is currently the only clinically proven treatment option for Leber's hereditary optic neuropathy (LHON) patients." | 2.53 | Idebenone for Leber's hereditary optic neuropathy. ( Gueven, N, 2016) |
| "Idebenone has been proposed as a means of bypassing defective complex I activity and a free radical scavenger to prevent oxidative damage." | 2.52 | Is there treatment for Leber hereditary optic neuropathy? ( Newman, NJ; Peragallo, JH, 2015) |
| "Leber's hereditary optic neuropathy is a rare genetic disorder affecting the retinal ganglion cells leading to a persistent severe bilateral loss of visual acuity within weeks or months." | 2.50 | [Leber's hereditary optic neuropathy - phenotype, genetics, therapeutic options]. ( Gallenmüller, C; Klopstock, T, 2014) |
| "Two months later, the diagnosis of Leber hereditary optic neuropathy (LHON) 11778/ND4 was established and the patient was treated with 900 mg of idebenone daily." | 2.48 | Is Leber hereditary optic neuropathy treatable? Encouraging results with idebenone in both prospective and retrospective trials and an illustrative case. ( Khaderi, KR; Sabet-Peyman, EJ; Sadun, AA, 2012) |
| "Oral treatment with idebenone 300 mg tid was started in seven patients 5 to 51 years after LHON onset." | 1.51 | Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset. ( Kircher, K; Pemp, B; Reitner, A, 2019) |
| "Idebenone is now a treatment option for LHON." | 1.48 | A teenager with acute bilateral visual loss. ( Jørstad, ØK; Kerty, E; Ødegaard, EM, 2018) |
| "Patients with Leber hereditary optic neuropathy (LHON) have a progressive decrease of their visual acuity which can deteriorate to <0." | 1.46 | Visual prognosis better in eyes with less severe reduction of visual acuity one year after onset of Leber hereditary optic neuropathy caused by the 11,778 mutation. ( Kigasawa, K; Mashima, Y; Oguchi, Y; Shinoda, K; Wakakura, M, 2017) |
| "He was diagnosed to have Leber's hereditary optic neuropathy with genetic workup showing G11778A mutation with over 80% heteroplasmy." | 1.40 | Novel use of idebenone in Leber's hereditary optic neuropathy in Hong Kong. ( Cheng, SW; Ko, CH; Lee, CY; Mak, C; Yau, SK; Yuen, YF, 2014) |
| " Consistent with the reported dosing and observed effects in LHON patients, we describe that in mice, idebenone penetrated into the eye at concentrations equivalent to those which protected RGC-5 cells from complex I dysfunction in vitro." | 1.38 | Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy. ( Anklin, C; Erb, M; Gueven, N; Heitz, FD; Pernet, V; Robay, D, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (4.35) | 29.6817 |
| 2010's | 28 (60.87) | 24.3611 |
| 2020's | 16 (34.78) | 2.80 |
| Authors | Studies |
|---|---|
| Varricchio, C | 1 |
| Beirne, K | 1 |
| Aeschlimann, P | 1 |
| Heard, C | 1 |
| Rozanowska, M | 1 |
| Votruba, M | 4 |
| Brancale, A | 1 |
| Varela-Fernández, R | 2 |
| Lema-Gesto, MI | 2 |
| González-Barcia, M | 2 |
| Otero-Espinar, FJ | 2 |
| Chan, JW | 1 |
| Sultan, W | 1 |
| Karanjia, R | 1 |
| Sadun, AA | 4 |
| Bendicho-Lavilla, C | 1 |
| Martin-Pastor, M | 1 |
| Herrero Vanrell, R | 1 |
| van Everdingen, JAM | 1 |
| Pott, JWR | 2 |
| Bauer, NJC | 1 |
| Krijnen, AM | 1 |
| Lushchyk, T | 1 |
| Wubbels, RJ | 1 |
| Borrelli, E | 1 |
| Berni, A | 1 |
| Cascavilla, ML | 1 |
| Barresi, C | 1 |
| Battista, M | 1 |
| Lari, G | 1 |
| Reibaldi, M | 1 |
| Bandello, F | 1 |
| Barboni, P | 3 |
| Schworm, B | 1 |
| Siedlecki, J | 1 |
| Catarino, C | 1 |
| von Livonius, B | 4 |
| Muth, DR | 1 |
| Rudolph, G | 4 |
| Havla, J | 1 |
| Klopstock, T | 9 |
| Priglinger, C | 3 |
| Baglivo, M | 1 |
| Nasca, A | 1 |
| Lamantea, E | 1 |
| Vinci, S | 1 |
| Spagnolo, M | 1 |
| Marchet, S | 1 |
| Prokisch, H | 1 |
| Catania, A | 1 |
| Lamperti, C | 1 |
| Ghezzi, D | 1 |
| Pemp, B | 1 |
| Kircher, K | 1 |
| Reitner, A | 1 |
| Finsterer, J | 2 |
| Catarino, CB | 3 |
| Banik, R | 1 |
| Matloob, S | 1 |
| Tamhankar, MA | 1 |
| Castillo, L | 1 |
| Friedburg, C | 1 |
| Halfpenny, CA | 1 |
| Lincoln, JA | 1 |
| Traber, GL | 1 |
| Acaroglu, G | 1 |
| Black, GCM | 1 |
| Doncel, C | 1 |
| Fraser, CL | 1 |
| Jakubaszko, J | 1 |
| Landau, K | 2 |
| Langenegger, SJ | 1 |
| Muñoz-Negrete, FJ | 1 |
| Newman, NJ | 6 |
| Poulton, J | 1 |
| Scoppettuolo, E | 1 |
| Subramanian, P | 1 |
| Toosy, AT | 1 |
| Vidal, M | 1 |
| Vincent, AL | 1 |
| Zarowski, M | 1 |
| Zermansky, A | 1 |
| Lob, F | 1 |
| Mikazans, O | 1 |
| Silva, M | 1 |
| Llòria, X | 1 |
| Metz, G | 3 |
| Ishikawa, H | 2 |
| Masuda, Y | 1 |
| Shikisima, K | 1 |
| Goseki, T | 1 |
| Kezuka, T | 1 |
| Terao, M | 1 |
| Miyazaki, A | 1 |
| Matsumoto, K | 1 |
| Nishikawa, H | 1 |
| Gomi, F | 1 |
| Mimura, O | 1 |
| Tonagel, F | 1 |
| Wilhelm, H | 1 |
| Richter, P | 1 |
| Kelbsch, C | 1 |
| Wang, Y | 1 |
| Hu, LF | 1 |
| Cui, PF | 1 |
| Qi, LY | 1 |
| Xing, L | 1 |
| Jiang, HL | 1 |
| Bianco, A | 1 |
| Bisceglia, L | 1 |
| Russo, L | 1 |
| Palese, LL | 1 |
| D'Agruma, L | 1 |
| Emperador, S | 1 |
| Montoya, J | 1 |
| Guerriero, S | 2 |
| Petruzzella, V | 1 |
| Bulwa, Z | 1 |
| Nichols, J | 1 |
| Gupta, N | 1 |
| Carelli, V | 3 |
| Carbonelli, M | 2 |
| de Coo, IF | 1 |
| Kawasaki, A | 1 |
| Lagrèze, WA | 2 |
| La Morgia, C | 2 |
| Orssaud, C | 2 |
| van Everdingen, J | 1 |
| Vignal-Clermont, C | 1 |
| Yu-Wai-Man, P | 4 |
| Mashima, Y | 1 |
| Kigasawa, K | 1 |
| Shinoda, K | 1 |
| Wakakura, M | 1 |
| Oguchi, Y | 1 |
| Jørstad, ØK | 2 |
| Ødegaard, EM | 2 |
| Heimdal, KR | 1 |
| Kerty, E | 2 |
| Theodorou-Kanakari, A | 1 |
| Karampitianis, S | 1 |
| Karageorgou, V | 1 |
| Kampourelli, E | 1 |
| Kapasakis, E | 1 |
| Theodossiadis, P | 1 |
| Chatziralli, I | 1 |
| Chang, M | 1 |
| Bidot, S | 1 |
| Lamirel, C | 1 |
| Brémond Gignac, D | 1 |
| Touitou, V | 1 |
| Vignal, C | 1 |
| Iyer, S | 1 |
| Gallenmüller, C | 2 |
| Cheng, SW | 1 |
| Ko, CH | 1 |
| Yau, SK | 1 |
| Mak, C | 1 |
| Yuen, YF | 1 |
| Lee, CY | 1 |
| Peragallo, JH | 1 |
| Eckenweiler, M | 1 |
| Gallenmueller, C | 1 |
| Korinthenberg, R | 1 |
| Kirschner, J | 1 |
| Lyseng-Williamson, KA | 1 |
| Schiff, M | 1 |
| Rustin, P | 1 |
| Gueven, N | 2 |
| Soiferman, D | 1 |
| Moore, DG | 1 |
| Burté, F | 1 |
| Saada, A | 1 |
| Szewka, AJ | 1 |
| Toffoli, D | 1 |
| Biousse, V | 1 |
| Dimitriadis, K | 2 |
| Rouleau, J | 2 |
| Heck, S | 2 |
| Bailie, M | 2 |
| Atawan, A | 1 |
| Chattopadhyay, S | 1 |
| Schubert, M | 1 |
| Garip, A | 1 |
| Kernt, M | 1 |
| Petraki, D | 1 |
| Rummey, C | 2 |
| Leinonen, M | 2 |
| Griffiths, PG | 2 |
| Meier, T | 3 |
| Chinnery, PF | 2 |
| Valentino, ML | 2 |
| Rizzo, G | 1 |
| De Negri, AM | 1 |
| Sadun, F | 1 |
| Carta, A | 1 |
| Simonelli, F | 1 |
| Aggarwal, D | 1 |
| Liguori, R | 2 |
| Avoni, P | 1 |
| Baruzzi, A | 2 |
| Zeviani, M | 1 |
| Montagna, P | 2 |
| Sabet-Peyman, EJ | 1 |
| Khaderi, KR | 1 |
| Heitz, FD | 1 |
| Erb, M | 1 |
| Anklin, C | 1 |
| Robay, D | 1 |
| Pernet, V | 1 |
| Büchner, B | 2 |
| Al-Tamami, J | 1 |
| Seidensticker, F | 1 |
| Nwali, N | 1 |
| Reznicek, L | 1 |
| Coppard, N | 1 |
| Barnils, N | 1 |
| Mesa, E | 1 |
| Muñoz, S | 1 |
| Ferrer-Artola, A | 1 |
| Arruga, J | 1 |
| Meletti, S | 1 |
| Vetrugno, R | 1 |
| Provini, F | 1 |
| Mancardi, GL | 1 |
| Bandini, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Patients With Leber's Hereditary Optic Neuropathy[NCT00747487] | Phase 2 | 85 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy[NCT01267422] | 9 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| A Randomized, Double-blinded, Placebo-controlled Trial of Idebenone in the Prevention of Episodic Migraine[NCT04151472] | Phase 3 | 180 participants (Anticipated) | Interventional | 2021-12-08 | Recruiting | ||
| A Single Visit, Observational, Follow-up Study of Patients With Leber's Hereditary Optic Neuropathy Following Participation in SNT-II-003 Trial[NCT01421381] | 60 participants (Actual) | Observational | 2011-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01267422)
Timeframe: Up to 3 years
| Intervention | mmHg (Mean) |
|---|---|
| IOP Before Treatment | 14 |
| IOP After Treatment | 16 |
The mean of Neutralizing antibody assay of 8 patients before and after treatment (NCT01267422)
Timeframe: up to 3 years
| Intervention | titer (Mean) |
|---|---|
| The Mean of Neutralizing Antibody Assay Before Treatment | 0.9221 |
| The Mean of Neutralizing Antibody Assay After Treatment | 0.8723 |
Average RNFL thickness of 8 patients througth Optical coherence tomography(OCT) test before and after treatment (NCT01267422)
Timeframe: Up to 3 years
| Intervention | Micrometer (Mean) | |
|---|---|---|
| injected eye | uninjected eye | |
| Average RNFL Thickness After Treatment | 46.7813 | 47.9688 |
| Average RNFL Thickness Before Treatment | 47.3125 | 50.1875 |
MD: mean deviation, the value Close to 0 regarded normal.VFI/MD：The bigger one was more close to the normal value. (NCT01267422)
Timeframe: up to 3 years
| Intervention | dB (Mean) | |
|---|---|---|
| injected eye | uninjected eye | |
| Mean MD After Treatment | -23.813 | -23.427 |
| Mean MD Before Treatment | -29.377 | -28.701 |
VFI: visual field index ,the value Close to 100% regarded normal. VFI/MD：The bigger one was more close to the normal value. (NCT01267422)
Timeframe: up to 3 years
| Intervention | Percentage of normal (Mean) | |
|---|---|---|
| injected eye | uninjected eye | |
| Mean VFI After Treatment | 28 | 25 |
| Mean VFI Before Treatment | 11 | 10.5 |
The mean percentage of CD3+/CD4+/CD8+ test before and after treatment (NCT01267422)
Timeframe: up to 6 months
| Intervention | Percentage of total cells (Mean) | ||
|---|---|---|---|
| Values of CD3+ | Values of CD4+ | Values of CD8+ | |
| The Mean Percentage of CD3+/CD4+/CD8+ After Treatment | 53 | 20 | 13 |
| The Mean Percentage of CD3+/CD4+/CD8+ Before Treatment | 51 | 26 | 20 |
(NCT01267422)
Timeframe: Up to 3 years
| Intervention | logMAR (Mean) | ||||
|---|---|---|---|---|---|
| before treament | 1 months after treament | 3 months after treament | 6 months after treament | 9 months after treament | |
| BCVA of Treated Eyes | 1.69 | 1.58 | 1.38 | 1.23 | 1.27 |
| BCVA of Un-treated Eyes | 1.40 | 1.36 | 1.31 | 1.20 | 1.23 |
7 reviews available for idebenone and Hereditary Optic Neuroretinopathy
| Article | Year |
|---|---|
Current and Emerging Treatment Modalities for Leber's Hereditary Optic Neuropathy: A Review of the Literature.
Topics: Antioxidants; Genetic Therapy; Humans; Optic Atrophy, Hereditary, Leber; Stem Cell Transplantation; | 2018 |
Novel therapeutic approaches for Leber's hereditary optic neuropathy.
Topics: Animals; Antioxidants; Dietary Supplements; Disease Models, Animal; DNA-Binding Proteins; DNA, Mitoc | 2013 |
[Leber's hereditary optic neuropathy - phenotype, genetics, therapeutic options].
Topics: Antioxidants; DNA, Mitochondrial; Genetic Predisposition to Disease; Humans; Molecular Diagnostic Te | 2014 |
Is there treatment for Leber hereditary optic neuropathy?
Topics: Animals; Genetic Counseling; Genetic Therapy; Humans; Mitochondria; Optic Atrophy, Hereditary, Leber | 2015 |
Idebenone in Friedreich ataxia and Leber's hereditary optic neuropathy: close mechanisms, similar therapy?
Topics: Antioxidants; Clinical Trials as Topic; Friedreich Ataxia; Humans; Optic Atrophy, Hereditary, Leber; | 2016 |
Idebenone for Leber's hereditary optic neuropathy.
Topics: Antioxidants; Humans; Optic Atrophy, Hereditary, Leber; Ubiquinone | 2016 |
Is Leber hereditary optic neuropathy treatable? Encouraging results with idebenone in both prospective and retrospective trials and an illustrative case.
Topics: Adult; Antioxidants; Clinical Trials as Topic; Female; Humans; Optic Atrophy, Hereditary, Leber; Pro | 2012 |
5 trials available for idebenone and Hereditary Optic Neuroretinopathy
| Article | Year |
|---|---|
Clinical outcomes of treatment with idebenone in Leber's hereditary optic neuropathy in the Netherlands: A national cohort study.
Topics: Antioxidants; Cohort Studies; Humans; Netherlands; Optic Atrophy, Hereditary, Leber; Retrospective S | 2022 |
Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Child; Female; Follow-Up Studies; Humans; Male; Middle Aged; | 2020 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Antioxidants; Contrast Sensitivity; DNA, Mitochondrial; Double-Blind Method | 2011 |
Effects of idebenone on color vision in patients with leber hereditary optic neuropathy.
Topics: Adolescent; Adult; Antioxidants; Color Perception; Double-Blind Method; Female; Humans; Male; Middle | 2013 |
Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy.
Topics: Adolescent; Adult; Aged; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Mal | 2013 |
34 other studies available for idebenone and Hereditary Optic Neuroretinopathy
| Article | Year |
|---|---|
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
Topics: Animals; Cell Survival; Dose-Response Relationship, Drug; Female; Hep G2 Cells; Humans; Mice; Mice, | 2020 |
Design, development, and characterization of an idebenone-loaded poly-ε-caprolactone intravitreal implant as a new therapeutic approach for LHON treatment.
Topics: Animals; Chemistry, Pharmaceutical; Chickens; Chorioallantoic Membrane; Delayed-Action Preparations; | 2021 |
Altering neuronal circuitry with 4-aminopyridine for visual improvement in Leber's hereditary optic neuropathy (LHON).
Topics: 4-Aminopyridine; Adult; DNA, Mitochondrial; Drug Therapy, Combination; Humans; Male; Nerve Net; Neur | 2022 |
Design, optimization, and in vitro characterization of idebenone-loaded PLGA microspheres for LHON treatment.
Topics: Humans; Microspheres; Optic Atrophy, Hereditary, Leber; Particle Size; Polylactic Acid-Polyglycolic | 2022 |
Visual Outcomes and Optical Coherence Tomography Biomarkers of Vision Improvement in Patients With Leber Hereditary Optic Neuropathy Treated With Idebenone.
Topics: Biomarkers; Cohort Studies; Humans; Optic Atrophy, Hereditary, Leber; Retinal Ganglion Cells; Retros | 2023 |
Age-dependent retinal neuroaxonal degeneration in children and adolescents with Leber hereditary optic neuropathy under idebenone therapy.
Topics: Adolescent; Child; Cross-Sectional Studies; Humans; Optic Atrophy, Hereditary, Leber; Retinal Gangli | 2023 |
Evaluation of Mitochondrial Dysfunction and Idebenone Responsiveness in Fibroblasts from Leber's Hereditary Optic Neuropathy (LHON) Subjects.
Topics: DNA, Mitochondrial; Fibroblasts; Humans; Mitochondria; Optic Atrophy, Hereditary, Leber | 2023 |
Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset.
Topics: Adult; Aged; Antioxidants; Chronic Disease; Follow-Up Studies; Forecasting; Humans; Male; Middle Age | 2019 |
Assessment of the Idebenone Effect on LHON Eyes Requires High-quality Studies.
Topics: DNA, Mitochondrial; Humans; Optic Atrophy, Hereditary, Leber; Ubiquinone | 2020 |
Characteristics of Japanese patients with Leber's hereditary optic neuropathy and idebenone trial: a prospective, interventional, non-comparative study.
Topics: Humans; Japan; Male; Optic Atrophy, Hereditary, Leber; Prospective Studies; Ubiquinone; Visual Acuit | 2021 |
Leber's hereditary optic neuropathy: course of disease in consideration of idebenone treatment and type of mutation.
Topics: DNA, Mitochondrial; Humans; Mutation; Optic Atrophy, Hereditary, Leber; Retrospective Studies; Ubiqu | 2021 |
Characteristics of Japanese patients with Leber's hereditary optic neuropathy and idebenone trial: a prospective, interventional, non-comparative study.
Topics: Humans; Japan; Optic Atrophy, Hereditary, Leber; Prospective Studies; Ubiquinone | 2021 |
Assessing the Treatment Effect of Idebenone in Leber Hereditary Optic Neuropathy Requires Appropriate Study Designs.
Topics: Antioxidants; DNA, Mitochondrial; Humans; Optic Atrophy, Hereditary, Leber; Ubiquinone | 2023 |
Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy-Response to Dr. Finsterer's Letter.
Topics: Antioxidants; Humans; Optic Atrophy, Hereditary, Leber; Ubiquinone | 2023 |
Pathologically Responsive Mitochondrial Gene Therapy in an Allotopic Expression-Independent Manner Cures Leber's Hereditary Optic Neuropathy.
Topics: Animals; Disease Models, Animal; DNA; DNA, Mitochondrial; Electron Transport Complex I; Fluorescent | 2021 |
High Mitochondrial DNA Copy Number Is a Protective Factor From Vision Loss in Heteroplasmic Leber's Hereditary Optic Neuropathy (LHON).
Topics: Antioxidants; Blindness; DNA Copy Number Variations; DNA, Mitochondrial; Female; Genes, Mitochondria | 2017 |
Clinical Reasoning: A 10-year-old boy with bilateral vision loss.
Topics: Antioxidants; Child; Humans; Male; Optic Atrophy, Hereditary, Leber; Ubiquinone; Vision, Low | 2017 |
International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Neuropathy.
Topics: Antioxidants; Congresses as Topic; Consensus; Disease Management; Humans; International Cooperation; | 2017 |
Visual prognosis better in eyes with less severe reduction of visual acuity one year after onset of Leber hereditary optic neuropathy caused by the 11,778 mutation.
Topics: Adolescent; Adult; Age of Onset; Aged; Antioxidants; Ascorbic Acid; Child; DNA Mutational Analysis; | 2017 |
Leber Hereditary Optic Neuropathy Caused by a Mitochondrial DNA 10663T>C Point Mutation and Its Response to Idebenone Treatment.
Topics: Consensus; DNA, Mitochondrial; Humans; Optic Atrophy, Hereditary, Leber; Point Mutation; Ubiquinone | 2018 |
A teenager with acute bilateral visual loss.
Topics: Adolescent; Antioxidants; Humans; Male; Ophthalmoscopy; Optic Atrophy, Hereditary, Leber; Point Muta | 2018 |
Leber's hereditary optic neuropathy misdiagnosed as optic neuritis and Lyme disease in a patient with multiple sclerosis.
Topics: Adult; Antioxidants; Diagnosis, Differential; Diagnostic Errors; Humans; Lyme Disease; Magnetic Reso | 2018 |
[Raxone in the Leber optical neuropathy: Parisian experience].
Topics: Adolescent; Adult; Disease Progression; Female; Humans; Male; Middle Aged; Optic Atrophy, Hereditary | 2019 |
Idebenone (Raxone°) and Leber hereditary optic neuropathy.
Topics: Antioxidants; Humans; Optic Atrophy, Hereditary, Leber; Treatment Outcome; Ubiquinone | 2017 |
Novel use of idebenone in Leber's hereditary optic neuropathy in Hong Kong.
Topics: Adolescent; Antioxidants; Diagnosis, Differential; Hong Kong; Humans; Male; Optic Atrophy, Hereditar | 2014 |
Mitochondrial DNA mutation 14487T>C manifesting as Leber's hereditary optic neuropathy.
Topics: Adolescent; DNA, Mitochondrial; Humans; Male; Mutation; NADH Dehydrogenase; Optic Atrophy, Hereditar | 2015 |
Idebenone: A Review in Leber's Hereditary Optic Neuropathy.
Topics: Antioxidants; Humans; Optic Atrophy, Hereditary, Leber; Randomized Controlled Trials as Topic; Ubiqu | 2016 |
Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy.
Topics: Adenosine Triphosphate; Adolescent; Antioxidants; Cells, Cultured; Energy Metabolism; Fibroblasts; H | 2017 |
Updates in neuro-ophthalmology. Highlights from the 37th annual meeting of the North American Neuro-Ophthalmology Society,February 5-10, 2011, Vancouver, Canada.
Topics: Burkholderia; Canada; Giant Cell Arteritis; Humans; Multiple Sclerosis; Neurology; Ophthalmology; Op | 2011 |
Idebenone treatment in Leber's hereditary optic neuropathy.
Topics: Antioxidants; Female; Humans; Male; Optic Atrophy, Hereditary, Leber; Placebos; Ubiquinone | 2011 |
Treatment of Leber hereditary optic neuropathy.
Topics: Antioxidants; Female; Humans; Male; Optic Atrophy, Hereditary, Leber; Placebos; Ubiquinone | 2011 |
Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy.
Topics: Administration, Oral; Animals; Antioxidants; Cell Line; Cell Survival; Disease Models, Animal; Drug | 2012 |
[Response to idebenone and multivitamin therapy in Leber's hereditary optic neuropathy].
Topics: Adult; Antioxidants; Ascorbic Acid; Benzoquinones; Female; Humans; Male; Optic Atrophy, Hereditary, | 2007 |
Leber's hereditary optic neuropathy (LHON/11778) with myoclonus: report of two cases.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Benzoquinones; Biopsy; Disease Progression; Electroen | 2001 |